Influence of internal structure and composition of liquid crystalline phases on topical delivery of paclitaxel

Journal of Pharmaceutical Sciences

Volumn 100, Issue 4, 2011, Pages 1444-1455

  Hosmer, Jaclyn M ^a   Shin, Soo H ^a   Nornoo, Adwoa ^b   Zheng, Haian ^a   Lopes, Luciana B ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b PALM BEACH ATLANTIC UNIVERSITY   (United States)

Author keywords

Formulation; Hexagonal phase; Lamellar phase; Lipids; Paclitaxel; Permeation enhancers; Skin; Transdermal

Indexed keywords

PACLITAXEL; WATER; ACYLGLYCEROL; ANTINEOPLASTIC AGENT; DRUG VEHICLE; MACROGOL DERIVATIVE; POLYOXYETHYLENE OLEYL ETHER; VEGETABLE OIL;

ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG ADMINISTRATION ROUTE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG PENETRATION; DRUG RELEASE; DRUG SOLUTION; DRUG STRUCTURE; FIBROBLAST; FLUORESCENCE; IN VITRO STUDY; LAMELLAR BODY; MICROSCOPY; NONHUMAN; STRATUM CORNEUM; ANIMAL; CHEMISTRY; INTRADERMAL DRUG ADMINISTRATION; LIQUID CRYSTAL; METABOLISM; PHASE TRANSITION; SKIN; SKIN ABSORPTION; SWINE;

ADMINISTRATION, CUTANEOUS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; GLYCERIDES; LIQUID CRYSTALS; PACLITAXEL; PHARMACEUTICAL VEHICLES; PHASE TRANSITION; PLANT OILS; POLYETHYLENE GLYCOLS; SKIN; SKIN ABSORPTION; SWINE; WATER;

EID: 79951902605     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22370     Document Type: Article

References (45)

1. Ganesh T. 2007. Improved biochemical strategies for targeted delivery of taxoids. Bioorg Med Chem 15(11):3597-3623.
2. Selimovic D, Hassan M, Haikel Y, Hengge UR. 2008. Taxol-induced mitochondrial stress in melanoma cells is mediated by activation of c-Jun N-terminal kinase (JNK) and p38 pathways via uncoupling protein 2. Cell Signal 20(2):311-322.
3. Barcelo R, Viteri A, Munoz A, Gil-Negrete A, Rubio I, Lopez-Vivanco G. 2006. Paclitaxel for progressive basal cell carcinoma. J Am Acad Dermatol 54(2 Suppl):S50-52.
4. Cheung MC, Pantanowitz L, Dezube BJ. 2005. AIDS-related malignancies: Emerging challenges in the era of highly active antiretroviral therapy. Oncologist 10(6):412-426.
5. Antman K, Chang Y. 2000. Kaposi's sarcoma. N Engl J Med 342(14):1027-1038.
6. Ferguson T, Wilcken N, Vagg R, Ghersi D, Nowak AK. 2007. Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst Rev (4):CD004421.
7. Khandavilli S, Panchagnula R. 2007. Nanoemulsions as versatile formulations for paclitaxel delivery: Peroral and dermal delivery studies in rats. J Invest Dermatol 127(1):154-162.
8. Barry BW. 2001. Novel mechanisms and devices to enable successful transdermal drug delivery. Eur J Pharm Sci 14(2):101-114.
9. Otto A, du Plessis J, Wiechers JW. 2009. Formulation effects of topical emulsions on transdermal and dermal delivery. Int J Cosmet Sci 31(1):1-19.
10. Alvarez-Roman R, Naik A, Kalia YN, Guy RH, Fessi H. 2004. Enhancement of topical delivery from biodegradable nanoparticles. Pharm Res 21(10):1818-1825.
11. Lopes LB, VanDeWall H, Li HT, Venugopal V, Li HK, Naydin S, Hosmer J, Levendusky M, Zheng H, Bentley MV, Levin R, Hass MA. 2010. Topical delivery of lycopene using microemulsions: Enhanced skin penetration and tissue antioxidant activity. J Pharm Sci 99(3):1346-1357.
12. Lopes LB, Lopes JL, Oliveira DC, Thomazini JA, Garcia MT, Fantini MC, Collett JH, Bentley MV. 2006. Liquid crystalline phases of monoolein and water for topical delivery of cyclosporin A: Characterization and study of in vitro and in vivo delivery. Eur J Pharm Biopharm 63(2):146-155.
13. Bender J, Ericson MB, Merclin N, Iani V, Rosen A, Engstrom S, Moan J. 2005. Lipid cubic phases for improved topical drug delivery in photodynamic therapy. J Control Release 106(3):350-360.
14. Ganem-Quintanar A, Quintanar-Guerrero D, Buri P. 2000. Monoolein: A review of the pharmaceutical applications. Drug Dev Ind Pharm 26(8):809-820.
15. Shin SC, Cho CW, Oh IJ. 2001. Effects of non-ionic surfactants as permeation enhancers towards piroxicam from the poloxamer gel through rat skins. Int J Pharm 222(2):199-203.
16. Lopes LB, Murphy N, Nornoo A. 2009. Enhancement of transdermal delivery of progesterone using medium-chain mono and diglycerides as skin penetration enhancers. Pharm Dev Technol 14(5):524-529.
17. Choi HK, Flynn GL, Amidon GL. 1995. Percutaneous absorption and dermal delivery of cyclosporin A. J Pharm Sci 84(5):581-583.
18. Guo J, Ping Q, Sun G, Jiao C. 2000. Lecithin vesicular carriers for transdermal delivery of cyclosporin A. Int J Pharm 194(2):201-207.
19. Duffy JF, Dijk DJ, Klerman EB, Czeisler CA. 1998. Later endogenous circadian temperature nadir relative to an earlier wake time in older people. Am J Physiol 275(5):R1478-1487.
20. Kingma BR, Frijns AJ, Saris WH, van Steenhoven AA, van Marken Lichtenbelt WD. 2010. Cold-induced vasoconstriction at forearm and hand skin sites: The effect of age. Eur J Appl Physiol 109(5):915-921.
21. Hosmer J, Reed R, Bentley MV, Nornoo A, Lopes LB. 2009. Microemulsions containing medium-chain glycerides as transdermal delivery systems for hydrophilic and hydrophobic drugs. AAPS PharmSciTech 10(2):589-596.
22. Nornoo AO, Zheng H, Lopes LB, Johnson-Restrepo B, Kannan K, Reed R. 2009. Oral microemulsions of paclitaxel: In situ and pharmacokinetic studies. Eur J Pharm Biopharm 71(2):310-317.
23. Kreilgaard M, Pedersen EJ, Jaroszewski JW. 2000. NMR characterisation and transdermal drug delivery potential of microemulsion systems. J Control Release 69(3):421-433.
24. Pollack GH. 2001. Cells, gels, and the engines of life: A new, unifying approach to cell biology. Seattle, WA, Ebner and Sons., pp 320.
25. Akhlaghi SP, Saremi S, Ostad SN, Dinarvand R, Atyabi F. 2010. Discriminated effects of thiolated chitosan-coated pMMA paclitaxel-loaded nanoparticles on different normal and cancer cell lines. Nanomedicine doi:10.1016/j.nano.2010.01.011.
26. Fojo T, Menefee M. 2007. Mechanisms of multidrug resistance: The potential role of microtubule-stabilizing agents. Ann Oncol 18 (Suppl 5):v3-8.
27. Pineiro D, Martin ME, Guerra N, Salinas M, Gonzalez VM. 2007. Calpain inhibition stimulates caspase-dependent apoptosis induced by taxol in NIH3T3 cells. Exp Cell Res 313(2):369-379.
28. Desai A, Vyas T, Amiji M. 2008. Cytotoxicity and apoptosis enhancement in brain tumor cells upon coadministration of paclitaxel and ceramide in nanoemulsion formulations. J Pharm Sci 97(7):2745-2756.
29. Wang Z, Diao Z, Liu F, Li G, Zhang G. 2006. Microstructure and rheological properties of liquid crystallines formed in Brij 97/water/IPM system. J Colloid Interface Sci 297(2):813-818.
30. Farkas E, Zelko R, Nemeth Z, Palinkas J, Marton S, Racz I. 2000. The effect of liquid crystalline structure on chlorhexidine diacetate release. Int J Pharm 193(2):239-245.
31. Ferrero C, Massuelle D, Jeannerat D, Doelker E. 2008. Towards elucidation of the drug release mechanism from compressed hydrophilic matrices made of cellulose ethers. I. Pulse-field-gradient spin-echo NMR study of sodium salicylate diffusivity in swollen hydrogels with respect to polymer matrix physical structure. J Control Release 128(1):71-79.
32. Makai M, Csanyi E, Nemeth Z, Palinkas J, Eros I. 2003. Structure and drug release of lamellar liquid crystals containing glycerol. Int J Pharm 256(1-2):95-107.
33. Isrealachvili JN. 1991. Intermolecular and surface forces. London: American press.
34. Muller-Goymann CC. 2004. Physicochemical characterization of colloidal drug delivery systems such as reverse micelles, vesicles, liquid crystals, and nanoparticles for topical administration. Eur J Pharm Biopharm 58(2):343-356.
35. Constantinides PP, Scalart JP, Lancaster C, Marcello J, Marks G, Ellens H, Smith PL. 1994. Formulation and intestinal absorption enhancement evaluation of water-in-oil microemulsions incorporating medium-chain glycerides. Pharm Res 11(10):1385-1390.
36. Zhao L, Feng SS. 2005. Effects of lipid chain unsaturation and headgroup type on molecular interactions between paclitaxel and phospholipid within model biomembrane. J Colloid Interface Sci 285(1):326-335.
37. Savic S, Savic M, Tamburic S, Vuleta G, Vesic S, Muller-Goymann CC. 2007. An alkylpolyglucoside surfactant as a prospective pharmaceutical excipient for topical formulations: the influence of oil polarity on the colloidal structure and hydrocortisone in vitro/in vivo permeation. Eur J Pharm Sci 30(5):441-450.
38. Holler S, Valenta C. 2007. Effect of selected fluorinated drugs in a "ringing" gel on rheological behaviour and skin permeation. Eur J Pharm Biopharm 66(1):120-126.
39. Brinon L, Geiger S, Alard V, Doucet J, Tranchant JF, Couarraze G. 1999. Percutaneous absorption of sunscreens from liquid crystalline phases. J Control Release 60(1):67-76.
40. Carr MG, Corsish J, Corrigan OI. 1997. Drug delivery from a liquid crystalline base across visking and human stratum corneum. Int J Pharm 157:35-42.
41. Niu G, Castro CH, Nguyen N, Sullivan SM, Hughes JA. 2010. In vitro cytotoxic activity of cationic paclitaxel nanoparticles on MDR-3T3 cells. J Drug Target 18(6):468-476.
42. Sawant RR, Torchilin VP. 2009. Enhanced cytotoxicity of TATp-bearing paclitaxel-loaded micelles in vitro and in vivo. Int J Pharm 374(1-2):114-118.
43. Tomita M, Hayashi M, Horie T, Ishizawa T, Awazu S. 1988. Enhancement of colonic drug absorption by the transcellular permeation route. Pharm Res 5(12):786-789.
44. Otto A, Wiechers JW, Kelly CL, Dederen JC, Hadgraft J, du Plessis J. 2010. Effect of emulsifiers and their liquid crystalline structures in emulsions on dermal and transdermal delivery of hydroquinone, salicylic acid, and octadecenedioic acid. Skin Pharmacol Physiol 23(5):273-282.
45. Savic S, Weber C, Savic MM, Muller-Goymann C. 2009. Natural surfactant-based topical vehicles for two model drugs: Influence of different lipophilic excipients on in vitro/in vivo skin performance. Int J Pharm 381(2):220-230.